During the past decade, Westwood Cardiology Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Westwood Cardiology Associates" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Westwood Cardiology Associates" are "Cardiovascular Disease" (2 trials). Many other conditions were trialed in "Westwood Cardiology Associates" in a lesser frequency.

Most popular intervention types in "Westwood Cardiology Associates" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Methotrexate" (1 trials) and "bococizumab (PF-04950615)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Westwood Cardiology Associates" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Westwood Cardiology Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Westwood Cardiology Associates, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Westwood Cardiology Associates, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".